Goldman Sachs
TYRA icon

Goldman Sachs’s Tyra Biosciences TYRA Stock Holding History

Goldman Sachs’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.1M Buy
550,334
+367,947
+202% +$11.9M ﹤0.01% 2385
2025
Q4 		$4.79M Buy
182,387
+82,237
+82% +$1.51M ﹤0.01% 3784
2025
Q3 		$1.4M Sell
100,150
-5,445
-5% -$62.1K ﹤0.01% 4791
2025
Q2 		$1.01M Buy
105,595
+27,589
+35% +$262K ﹤0.01% 4696
2025
Q1 		$725K Buy
78,006
+13,896
+22% +$180K ﹤0.01% 4936
2024
Q4 		$891K Sell
64,110
-24,971
-28% -$453K ﹤0.01% 4898
2024
Q3 		$2.09M Sell
89,081
-25,793
-22% -$541K ﹤0.01% 4119
2024
Q2 		$1.84M Buy
114,874
+100,797
+716% +$1.74M ﹤0.01% 3982
2024
Q1 		$231K Buy
+14,077
New +$231K ﹤0.01% 5070
2021
Q4 		– Sell
-207,283
Closed -$3.65M – 6713
2021
Q3 		$3.65M Buy
+207,283
New +$3.96M ﹤0.01% 3621

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Goldman Sachs's TYRA Position: Q1 2026 in Review

Goldman Sachs increased its Tyra Biosciences (TYRA) stake by 202% in Q1 2026, buying an estimated $11.9M and bringing the position to 550,334 shares worth $21.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2385.

Goldman Sachs first reported a position in TYRA in Q3 2021 and has held it in 10 quarters since. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Goldman Sachs held 550,334 shares of Tyra Biosciences worth $21.1M as of Q1 2026.
  • Goldman Sachs bought 367,947 Tyra Biosciences shares in Q1 2026, an estimated $11.9M.
  • Tyra Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2385 holding.
  • Goldman Sachs first reported a position in Tyra Biosciences in Q3 2021 and has held it in 10 quarters since.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.